Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.490
+0.100 (4.18%)
At close: Jul 17, 2026, 4:00 PM EDT
2.450
-0.040 (-1.61%)
After-hours: Jul 17, 2026, 6:19 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 16 employees as of December 31, 2025. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$2,352,563
Market Cap
21.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2024 | 15 | 3 | 25.00% | 15 | 0 |
| Dec 31, 2023 | 12 | 1 | 9.09% | 12 | 0 |
| Dec 31, 2022 | 11 | 3 | 37.50% | 11 | 0 |
| Dec 31, 2021 | 8 | 0 | - | 6 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 115 |
| Longeveron | 38 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| Neuphoria Therapeutics | 8 |
ATOS News
- 10 days ago - Atossa Therapeutics initiated with a Buy at Rodman & Renshaw - TheFly
- 5 weeks ago - Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PRNewsWire
- 5 weeks ago - Atossa Therapeutics announces registered direct offering of up to $16.5M - TheFly
- 5 weeks ago - Atossa Therapeutics announces $16.5M registered direct offering - TheFly
- 5 weeks ago - Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PRNewsWire
- 7 weeks ago - Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PRNewsWire
- 2 months ago - Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy - PRNewsWire
- 2 months ago - Atossa Therapeutics Transcript: Status update - Transcripts